Therapeutic management of breast cancer in the elderly

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 6, 2011, Pages 945-960

  Spazzapan, Simon ^a   Crivellari, Diana ^a   Bedard, Philippe ^a   Lombardi, Davide ^a   Miolo, Gianmaria ^a   Scalone, Simona ^a   Veronesi, Andrea ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

ageing; breast cancer; elderly; treatment

Indexed keywords

AMFEBUTAMONE; ANASTROZOLE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CLODRONIC ACID; CLOPIDOGREL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FLUOROURACIL; FLUOXETINE; FULVESTRANT; GEMCITABINE; IBANDRONIC ACID; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PAROXETINE; PLACEBO; RALOXIFENE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADL DISABILITY; AGED; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD TOXICITY; BONE DEMINERALIZATION; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CATARACT; CHEMOTHERAPY INDUCED EMESIS; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENDOMETRIUM CANCER; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FRACTURE; GERIATRIC ASSESSMENT; HOT FLUSH; HUMAN; LIFE EXPECTANCY; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PLASMA HALF LIFE; PROGNOSIS; REVIEW; SIDE EFFECT; STROKE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VAGINA DISCHARGE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIFE EXPECTANCY;

EID: 79952741026     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.540570     Document Type: Review

References (128)

1. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol 2004;31:128-36 (Pubitemid 38481234)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
3. Newschaffer CJ, Penberthy L, Desch CE, et al. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996;156:85-90 (Pubitemid 26011595)
4. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Patterns of care related to age of breast cancer patients. JAMA 1987;257:2766-70 (Pubitemid 17066520)
5. Satariano WA. Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. J Gerontol 1992;47(Spec No):24-31
6. Harlan LC, Klabunde CN, Ambs AH, et al. Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv 2009;3:89-98
7. Satariano WA, Ragland DR The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10 (Pubitemid 24027550)
8. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44 (Pubitemid 34251967)
9. Reuben DB, Rubenstein LV, Hirsch SH, Hays RD. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 1992;93:663-9
10. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 2007;55:780-91 (Pubitemid 46668974)
11. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709-17 (Pubitemid 30220549)
12. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44 (Pubitemid 47244357)
13. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29
14. Carlson RW, Moench S, Hurria A, et al. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw 2008;6(Suppl 4):S1-25; quiz S26-7
15. Louwman WJ, Vulto JC, Verhoeven RH, et al. Clinical epidemiology of breast cancer in the elderly. Eur J Cancer 2007;43:2242-52 (Pubitemid 47554512)
16. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-6 (Pubitemid 30212316)
17. Crivellari D, Aapro M, Leonard R, et al. Breast cancer in the elderly. J Clin Oncol 2007;25:1882-90 (Pubitemid 46854422)
18. Daidone MG, Coradini D, Martelli G, Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 2003;45:313-25 (Pubitemid 36299137)
19. Durbecq V, Ameye L, Veys I, et al. A significant proportion of elderly patients develop hormone-dependant 'luminal-B' tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008;67:80-92
20. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74 (Pubitemid 39100473)
21. Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28:1684-91
22. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800
23. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116:295-302
24. Bedard PL, Mook S, Knauer M, et al. The 70-Gene Profile (MammaPrintTM) Is an Independent Predictor of Breast Cancer Specific Survival for women 65 years of age or older. Cancer Res 2009;69(24), Supplement DOI: 10.1158/0008-5472. SABCS-09-4049
25. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34 (Pubitemid 46622311)
26. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65
27. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91 (Pubitemid 32176272)
28. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716-25 (Pubitemid 46179461)
29. Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 2009;10:1070-6
30. Aapro M, Monfardini S, Jirillo A, Basso U. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treat Rev 2009;35:503-8
31. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
32. Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 2010;102:942-9
33. Crivellari D, Price K, Gelber RD, et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 2003;21:4517-23 (Pubitemid 46594021)
34. Wiseman H, Paganga G, Rice-Evans C, Halliwell B. Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen? Biochem J 1993;292(Pt 3):635-8 (Pubitemid 23210187)
35. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406 (Pubitemid 23264348)
36. Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 2003;79:11-16
37. Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001;93:16-21 (Pubitemid 32060885)
38. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-47 (Pubitemid 37510624)
39. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 (Pubitemid 44050394)
40. Sideras K, Ingle JN, Ames MM, et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010;28:2768-76
41. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9 (Pubitemid 34694019)
42. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2
43. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
44. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57 (Pubitemid 43016814)
45. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715-22
46. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76
47. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008;26:1972-9
48. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-96
49. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549-55 (Pubitemid 351264347)
50. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42
51. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055-63
52. Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006;24:2757-64 (Pubitemid 46630573)
53. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006;24:2750-6 (Pubitemid 46630572)
54. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA 1992;268:57-62
55. Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 1996;156:882-8 (Pubitemid 26120594)
56. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293:1073-81 (Pubitemid 40300281)
57. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-65
58. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007;25:3808-15 (Pubitemid 47477254)
59. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699-709 (Pubitemid 34567375)
60. Bria E, Nistico C, Cuppone F, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006;106:2337-44 (Pubitemid 43787656)
61. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53
62. Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;4:CD004421
63. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67
64. Hayes DF, Thor AD, Dressler LG, et al. HER-2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506 (Pubitemid 47572635)
65. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71 (Pubitemid 351549913)
66. Nuzzo F, Morabito A, De Maio E, et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Crit Rev Oncol Hematol 2008;66:171-80
67. Perez EA, Vogel CL, Irwin DH, et al. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 2002;73:85-8 (Pubitemid 34548168)
68. Del Mastro L, Perrone F, Repetto L, et al. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005;16:253-8 (Pubitemid 40309305)
69. ten Tije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004;40:352-7 (Pubitemid 38121271)
70. Biganzoli L, Licitra S, Moretti E, et al. Taxanes in the elderly: can we gain as much and be less toxic? Crit Rev Oncol Hematol 2009;70:262-71
71. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177-83
72. Aapro M, Schwenkglenks M, Lyman GH, et al. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010;74:203-10
73. Flores IQ, Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clin J Oncol Nurs 2010;14:81-6
74. Chavez-MacGregor M, Gonzalez-Angulo AM. HER-2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0, M0): a high risk group? Clin Adv Hematol Oncol 2009;7:591-8
75. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36 (Pubitemid 46039831)
76. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2neu positive early breast cancer patients. Available from: http://www. sabcs.org/2006
77. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 2005;353:1673-84 (Pubitemid 41464706)
78. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20 (Pubitemid 43290919)
79. Sledge GW, O'Neill A, Thor A, et al. Adjuvant trastuzumab: long-term results of E2198. SABCS. Available from: http://www.posters2view.com/sabcs06/ view.php?nu=2006
80. Madarnas Y, Trudeau M, FranekJA, et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008;34:539-57
81. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25:3859-65 (Pubitemid 47477261)
82. Biganzoli L, Licitra S, Claudino W, et al. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients-a jungle? Eur J Cancer 2007;43:2270-8 (Pubitemid 47539119)
83. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403
84. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95
85. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5
86. Pritchard KI, Rolski J, Papai Z, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010;123:453-61
87. Ohno S, Rai Y, Iwata H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 2010;21:2342-7
88. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80 (Pubitemid 34436728)
89. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6 (Pubitemid 36951001)
90. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43 (Pubitemid 35424084)
91. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006;24:3623-8 (Pubitemid 46630536)
92. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61 (Pubitemid 46780635)
93. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82 (Pubitemid 43985242)
94. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22 (Pubitemid 46698462)
95. Nicolella D, Grimaldi G, Colantuoni G, et al. Weekly low dose epirubicin in elderly cancer patients. Tumori 1996;82:369-71 (Pubitemid 26352957)
96. Huober J, Fett W, Nusch A, et al. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer 2010;10:2 DOI: 10.1186/1471-2407-10-2
97. Basso U, Roma A, Falci C, et al. Biweekly liposomal pegylated doxorubicin in elderly women with advanced breast cancer: a prospective multicenter trial focusing on tolerability and cardiotoxicity. J Clin Oncol 2010;28(Suppl): abstract 1138
98. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-61 (Pubitemid 46218707)
99. Schott AF, Lew D, Barlow WE, et al. Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). J Clin Oncol 2010;28(Suppl);abstract 1006
100. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
101. Brunello A, Monfardini S, Crivellari D, et al. Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (> = 70 years). J Clin Oncol (Meeting Abstracts) 2008;26:1096
102. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7 (Pubitemid 30035956)
103. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol 2003;21:1618-23 (Pubitemid 46594117)
104. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-9 (Pubitemid 46606420)
105. Reed MW, Wyld L, Ellis P, et al. Breast cancer in older women: trials and tribulations. Clin Oncol (R Coll Radiol) 2009;21:99-102
106. Fumoleau P, Cortes-Funes H, Taleb AB, et al. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol 29 May 2009. [Epub ahead of print]
107. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8
108. Twelves C, Loesch D, Blum JL, et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (Meeting Abstracts) 2010;28:CRA1004
109. Available from: http://www.drugs.com/drug-interactions/letrozole.html. 2010
110. Available from: http://www.drugs.com/drug-interactions/tamoxifen.html. 2010
111. Available from: http://www.micromedex. com. 2010
112. Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: cancer and leukemia group B (CALGB 9762). J Clin Oncol 2006;24:1846-51 (Pubitemid 46638982)
113. Smorenburg CH, ten Tije AJ, Verweij J, et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003;39:196-202 (Pubitemid 36057070)
114. Ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070-7 (Pubitemid 46202261)
115. Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12:6100-5 (Pubitemid 44703775)
116. Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005;23:4424-9 (Pubitemid 46207017)
117. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997;33:301-3
118. Gauvin A, Pinguet F, Culine S, et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 2000;6:2690-5 (Pubitemid 30482105)
119. Puozzo C, Gridelli C Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics. Clin Lung Cancer 2004;5:237-42 (Pubitemid 38312740)
120. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 2007;25:1832-43 (Pubitemid 46860272)
121. VenookAP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia Group B 9565. J Clin Oncol 2000;18:2780-7 (Pubitemid 30463562)
122. Shepherd FA, Cormier Y, Burkes R, et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 1997;24:S8-27-30
123. Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453-60 (Pubitemid 29501014)
124. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003;51:395-402 (Pubitemid 36649136)
125. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-9 (Pubitemid 30485668)
126. Bononi A, Gusella M, Modena I, et al. Pharmacokinetic study of pegylated liposomal doxorubicin (PLD) in patients over 70: association with increasing age and cutaneous toxicity. J Clin Oncol 2010;28(15s):abstract 9155
127. Hurria A, Lichtman SM. Pharmacokinetics of chemotherapy in the older patient. Cancer Control 2007;14:32-43 (Pubitemid 46168964)
128. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007;110:1376-84 (Pubitemid 47435612)